George Scangos left Biogen on an up note, but the company has plenty of challenges ahead. For his final year as CEO, Scangos' total compensation added up to $17.73 million.
Some of the executive pay rankings are predictable, like Johnson & Johnson's CEO, regardless who's in the job. What's not guaranteed is that the chairman of a generics maker in hot water with the U.S. government and American parents—Mylan's Robert Coury—would step off the company’s employee roster and into the nonexecutive chairman’s job and reap a $97 million package with the move.
A U.S. appeals court sided with Biogen in a lawsuit claiming execs weren't open with investors about Tecfidera's sales trajectory after the death of a patient taking the drug.
On its annual list of the world’s 100 top CEOs, Harvard Business Review tagged 5 biopharma execs--and one, Novo Nordisk CEO Lars Rebien Sørensen, took the No. 1 slot for the second year in a row. Thing is, two of those 5 are on their way out.
What a difference a year made for Biogen CEO George Scangos. Slowing MS sales last year weren't just a drag on Biogen's revenue--they also took a $2M-plus bite out of Scangos' 2015 compensation.
